Charlotte-area resident Vickie Johnson, 72, was diagnosed with colon cancer in 2018 after seeking care twice for abdominal pain.

Connor McMahon was treated at a children’s hospital in Atlanta for leukemia, first at three years old, then eight years later when he was 12. When he relapsed again at 15, he traveled to Duke for a clinical trial of a first-of-its kind treatment.

MD & MDiv grad Monica Bodd thinks a lot about the patient experience and how to make it better — both through research and clinical practice. You can take the doctor out of Duke, but you can't take Duke out of the doctor.

The 2023 event topped 200 men screened/assessed for prostate, skin, lung, and colorectal cancer as well as diabetes and heart disease.

Eleanor Scott Bell, 79, was born and raised in Lumberton, the capital of Robeson County in North Carolina. One of her earliest memories is of picking tobacco to supplement the family income. They were a family of nine with a large extended family.

Omidubicel, a novel cellular therapy, expands the availability of donor stem cell transplants to more patients.

Research that originated in a DCI laboratory contributed to recent FDA approval of the first new endocrine therapy for breast cancer since 2002, Elacestrant.

For the first time since 2019, the DCI Scientific Retreat was held in person with a full program followed by a poster session and mingling — attracted around 90 faculty, staff, and trainees.

(Clinical Practice Today is a publication targeted at Duke Health Referring Physicians)

Learn how Duke/DCI is expanding its footprint in next generation cancer sequencing tech via the Clinical Molecular Diagnostics Laboratory.

Learn how the Precision Cancer Medicine Initiative, run jointly by DCI and the Duke Dept. of Pathology, is advancing research, extending lives, and breaking down barriers to access.

The Duke BioRepository & Precision Pathology Center grew, thrived, and progressively built a national reputation. “Its success represents the evolution and extension of the Department of Pathology’s support and commitment to cancer research."

More than 1.5 million women in the U.S. are currently on endocrine therapies (hormone therapies) for breast cancer. These drugs and drug combinations have been found to work well, in some cases for many years, until they don’t.

Duke Health leadership launched Translating Duke Health in 2017 as a multi-disciplinary, multi-year commitment to capitalize on Duke’s collective strengths in research, clinical care, and population health to address major health challenges. This…

The Society of Nuclear Medicine & Molecular Imaging has designated the Division of Nuclear Medicine and Radiotheranostics at Duke Health as a Comprehensive Radiopharmaceutical Therapy Center of Excellence.

Seagen Inc. announced positive topline results last month of a pivotal phase 2 clinical trial (called MOUNTAINEER) of a novel drug combination for HER2-positive metastatic colorectal cancer. DCI led the trial and enrolled the trial's first patient.

Janel Keaton has been able to travel for weddings and grandbabies and enjoy mountain hikes and coastal cycling as a stage 4 breast cancer patient, thanks, in part, to the Duke Center for Brain and Spine Metastasis who had her back all along the way.